Last reviewed · How we verify
NCT05830097
A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors
Phase 1, PHASE2 trial testing CBP-1019 in Cancer, Breast in 260 participants. Status unknown.
30 June 2025
Quick facts
| Lead sponsor | Coherent Biopharma (Hefei) Co., Ltd. |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 260 |
| Start date | 14 March 2023 |
| Primary completion | 30 June 2025 |
| Estimated completion | 30 September 2025 |
| Sites | 5 locations across China, United States |
Drugs / interventions tested
- CBP-1019 — full drug profile →
Conditions studied
- Cancer, Breast — all drugs for Cancer, Breast →
- Cancer, Lung — all drugs for Cancer, Lung →
- Cancer of Pancreas — all drugs for Cancer of Pancreas →
- Cancer of Esophagus — all drugs for Cancer of Esophagus →
Sponsor
Coherent Biopharma (Hefei) Co., Ltd.
Who can join
18 and older, any sex, with Cancer, Breast or Cancer, Lung. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of this phase I study is to evaluate the safety and potential efficacy and to determine the recommended phase 2 dose (RP2D) of CBP-1019, a bi-specific ligand conjugated drugs in patients with advanced solid tumors.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Colorectal Cancer: Disease Process, Current Treatment Options, and Future Perspectives.
Adebayo AS, Agbaje K, Adesina SK, Olajubutu O. · · 2023 · cited 65× · PMID 38004598 · DOI 10.3390/pharmaceutics15112620
Verify or expand the search:
- PubMed search for NCT05830097
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of CBP-1019
Trials testing the same drug.
- NCT06576037 — Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRP · Phase 1 · recruiting
Other recruiting trials for Cancer, Breast
Currently open trials in the same condition.
- NCT06672120 — Exercise in Triple- Negative Breast Cancer · NA · recruiting
- NCT06345534 — FAST-FORWARD vs HAI5 · NA · recruiting
- NCT05721976 — With Love, Grandma ("Con Cariño, Abuelita") Pilot Study · NA · recruiting
- NCT04258813 — Onco-primary Care Networking to Support TEAM-based Care · NA · active not recruiting
- NCT05289258 — Unified Barlow Protocol (UP) in Cancer Survivors for Cognitive Impairments · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05830097 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Coherent Biopharma (Hefei) Co., Ltd.
- Last refreshed: 26 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05830097.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing